 | Up a level |
Pennell, D. and Porter, J.B. and Cappellini, M.D. and Chan, L.L. and El-Beshlawy, A. and Aydinok, Y. and Ibrahim, H. and Li, Chi-Kong and Viprakasit, V. and Elalfy, M.S. and Kattamis, A. and Smith, G. and Habr, D. and Domokos, G. and Roubert, B. and Taher, A. (2010) Continued improvement and normalization of myocardial T2*in patients with beta-thalassemia major treated with deferasirox (Exjade (R)) for up to 3 years. Blood, 116 (21). pp. 1735-1736.
Pennell, D. and Porter, J. and Cappellini, M. and Chan, L.L. and El-Beshlawy, A. and Aydinok, Y. and Ibrahim, H. and Li, C.K. and Viprakasit, V. and Elalfy, M. and Kattamis, A. and Smith, G. and Habr, D. and Roubert, B. and Taher, A. (2010) Continued improvement in cardiac T2*with deferasirox treatment over 2 years: Results from the extension of epic cardiac substudy in beta-thalassaemia patients with myocardial siderosis. Haematologica-The Hematology Journal, 95 (2). pp. 202-203.
Pennell, D. and Porter, J. and Cappellini, M. and Chan, L.L. and El-Beshlawy, A. and Aydinok, Y. and Ibrahim, H. and Li, C.K. and Viprakasit, V. and Elalfy, M. and Kattamis, A. and Smith, G. and Habr, D. and Roubert, B. and Taher, A. (2010) Deferasirox effectively removes cardiac iron in beta-thalassaemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine-deferiprone therapy. Haematologica-The Hematology Journal, 95 (2). p. 699.
